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Abstract
Background: The incidence of acute kidney injury (AKI) is increasing globally and it is much more common than end-stage
kidney disease. AKI is associated with high mortality and cost of hospitalisation. Studies of treatments to reduce this high
mortality have used differing renal replacement therapy (RRT) modalities and have not shown improvement in the short
term. The reported long-term outcomes of AKI are variable and the effect of differing RRT modalities upon them is not clear.
We used the prolonged follow-up of a large clinical trial to prospectively examine the long-term outcomes and effect of RRT
dosing in patients with AKI.
Methods and Findings: We extended the follow-up of participants in the Randomised Evaluation of Normal vs. Augmented
Levels of RRT (RENAL) study from 90 days to 4 years after randomization. Primary and secondary outcomes were mortality
and requirement for maintenance dialysis, respectively, assessed in 1,464 (97%) patients at a median of 43.9 months
(interquartile range [IQR] 30.0–48.6 months) post randomization. A total of 468/743 (63%) and 444/721 (62%) patients died
in the lower and higher intensity groups, respectively (risk ratio [RR] 1.04, 95% CI 0.96–1.12, p= 0.49). Amongst survivors to
day 90, 21 of 411 (5.1%) and 23 of 399 (5.8%) in the respective groups were treated with maintenance dialysis (RR 1.12, 95%
CI 0.63–2.00, p= 0.69). The prevalence of albuminuria among survivors was 40% and 44%, respectively (p= 0.48). Quality of
life was not different between the two treatment groups. The generalizability of these findings to other populations with
AKI requires further exploration.
Conclusions: Patients with AKI requiring RRT in intensive care have high long-term mortality but few require maintenance
dialysis. Long-term survivors have a heavy burden of proteinuria. Increased intensity of RRT does not reduce mortality or
subsequent treatment with dialysis.
Trial registration: http://www.ClinicalTrials.gov NCT00221013
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Introduction
Acute kidney injury (AKI) is approximately ten times more
common than end-stage kidney disease [1], and the incidence is
increasing worldwide [2,3]. Short-term mortality rates of patients
with AKI are in excess of 40%, predominantly in those who
require renal replacement therapy (RRT) [4].
The longer term outcomes of patients with AKI are less clear.
Existing descriptions of these outcomes have used variable
methodologies and have been obtained from retrospectively
defined cohorts. Whilst some have been population-based cohorts
[5,6], many have been based upon specific disease groups [7–9].
In addition, the AKI cohorts are often defined using post-AKI
exposure data, such as hospitalization coding [10] or based upon
survival of the acute hospitalization [6]. For clinicians, when
managing patients presenting with AKI, these factors limit the
applicability of these studies.
Following an episode of AKI, the balance of the risks of
mortality and that of subsequent chronic kidney disease (CKD)
remains uncertain. A recent meta-analysis by Coca and colleagues
[11] reported absolute rates of CKD following AKI approximately
50% higher than that for mortality, but was limited by a high
degree of statistical heterogeneity. A large population cohort study
in 2009 concluded that AKI necessitating in-hospital dialysis was
associated with an increased risk of chronic dialysis but not an
increase in all-cause mortality [5].
Patients with AKI managed in an intensive care unit (ICU)
often require RRT and have the highest short-term mortality of
any group with AKI [4]. Studies that have examined different dose
intensities of RRT have not demonstrated improvements in short-
term outcomes [12]. Longer term outcomes of patients treated
with different intensities of RRT are unknown.
We previously conducted a randomized-controlled trial com-
paring higher and lower intensities of continuous RRT [13] in
ICU patients with AKI and demonstrated no difference in all-
cause mortality at 90 days between the two groups. The aim of this
study was to extend follow-up to up to four years and report
longer-term mortality (along with the variables that may predict
mortality), treatment with chronic dialysis, and functional




A description of the Randomized Evaluation of Normal vs.
Augmented Levels of renal replacement therapy (RENAL) study
design has been previously published [14]. In brief, it was a
parallel group, open-label, randomized-controlled trial in 1,508
ICU patients with AKI requiring RRT from 35 centres in
Australia and New Zealand between December 2005 and August
2008. Patients in ICU aged 18 or older, deemed by the treating
clinician to require RRT and meeting at least one of the following
criteria, were eligible for enrolment: oliguria (urine output ,
100 ml in a 6-hour period) that was unresponsive to fluid
resuscitation, serum potassium exceeding 6.5 mmol per litre,
severe acidaemia (pH,7.2), a plasma urea nitrogen above
25 mmol per litre (70 mg per decilitre), a serum creatinine
concentration above 300 mmol per litre (3.4 mg per decilitre), or
the presence of clinically significant organ oedema (e.g., pulmo-
nary oedema). Eligible patients were randomly assigned to receive
25 ml/kg/h (lower intensity) or 40 ml/kg/h (higher intensity) of
continuous haemodiafiltration and were followed to 90 days after
randomization. Study treatment was ceased when any of five pre-
defined criteria were met: withdrawal of consent, death, discharge
from ICU, when intermittent dialysis was considered preferable to
continuous RRT for the patient, or when the treating clinicians
considered that RRT was no longer required.
The Prolonged Outcomes Study of RENAL (POST-RENAL)
was an investigator-initiated, prospective, extended follow-up of
the RENAL study, funded by a project grant from the Australian
National Health and Medical Research Council. The study was
designed and managed by the study management committee and
endorsed by the Australia and New Zealand Intensive Care
Society Clinical Trials Group. The study protocol was approved
by human research ethics committees at each of the participating
centres and centrally by the Australian Institute for Health and
Welfare Ethics Committee. Statistical analyses were conducted at
the George Institute for Global Health.
Study Participants
All participants in the RENAL study were included in the
primary and secondary outcomes of the POST-RENAL study.
Tertiary outcomes were obtained in the subset of consenting
survivors. Ethics committee approval granted a waiver of the
requirement for individual consent to link to state and national
registries, whereupon survivors were approached for written
informed consent to participate in the collection of the tertiary
outcomes for the POST-RENAL study.
Follow-up
Using the RENAL Study database, we identified all participants
alive at day 90 following randomization. The initials and study
numbers of these participants were provided to all the participat-
ing centres who then added patient identifiers to these data. These
data were then used to link to mortality registries in all Australian
states and nationally in New Zealand, along with the Australia and
New Zealand Dialysis and Transplant (ANZDATA) Registry. In
addition, study centres used medical records along with contact
details to ascertain the survival and dialysis status of patients.
The following registries were accessed to contribute to the
primary and secondary outcomes of the POST-RENAL study:
Data Linkage Unit, Australian Institute of Health and Welfare
National Death Index, Canberra, Australia (accessed July 2010,
October 2010, January 2011, and September 2011); NZ Births,
Deaths and Marriages Registry, Department of Internal Affairs,
Wellington, New Zealand; Victorian Registry of Births, Deaths
and Marriages, Victoria, Australia (accessed October 2010 and
January 2012); Research and Statistics, Department of Justice,
Queensland, Australia (accessed October 2010 and July 2011);
NSW Registry Births Deaths and Marriages, New South Wales,
Australia (accessed October 2010, April 2011 and October 2011);
WA Registry of Births, Deaths and Marriages, Western Australia,
Australia (accessed October 2010); Consumer and Business
Services, Births, Deaths and Marriages Registration Office, South
Australia, Australia (accessed October 2011); Births, Deaths and
Marriages – ACT, Australian Capital Territory, Australia
(accessed October 2011); Australia and New Zealand Dialysis
and Transplant (ANZDATA) Registry, South Australia, Australia
(accessed March 2011 and January 2012).
Outcome Measures
The primary outcome measure was all-cause mortality 3.5 years
after randomization. This measure was assessed by follow-up from
the study centres and by linking to state and national death
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registries. Causes of death were independently adjudicated by two
medical practitioners from death certificate data, with consensus
arrived at for any discrepant classifications. The secondary
outcome was treatment with maintenance dialysis (defined as
entry to a chronic dialysis program and meeting criteria for
inclusion in the national dialysis registry) during the 3.5 years
following randomization. Information on maintenance dialysis was
obtained by follow-up from the study centres and by linkage to the
Australian and New Zealand Dialysis and Transplant (AN-
ZDATA) Registry.
Tertiary outcomes were quantification of renal function in
survivors determined by serum creatinine and estimated glomerular
filtration rate (eGFR) using the Modification of Diet in Renal
Disease Study Group (MDRD) formula [15]; prevalence of
proteinuria measured by spot urinary albumin to creatinine ratio
(ACR); blood pressure and receiving treatment to lower blood
pressure; quality of life using the EuroQol Group 5 dimension tool
(EQ-5D) [16]; and the 12 variable Short Form Health Survey (SF-
12) [17]. EQ-5D derives a score after assigning the worst imaginable
health state a value of 0 and the best imaginable health state a value
of 1, although it does permit negative scores. SF-12 uses eight
domains, with scores ranging from 0 to 100, that allow aggregation
into physical health and mental health composite scores, with higher
scores representing better quality of life.
Quality of life was assessed by telephone interviewers based at
the George Institute for Global Health; the interviewers were
blinded to original study treatment allocation.
Baseline characteristics of the study population included
demographic and laboratory variables, the presence of sepsis
(defined by the presence of a focus of infection and two systemic
inflammatory response syndrome criteria [18] within 24 hours
following randomization), the Acute Physiology and Chronic
Health Evaluation (APACHE) III score (a severity of illness score
ranging from 0 to 299, with higher scores indicating more severe
illness [19]), and the Sequential Organ Failure Assessment (SOFA)
Figure 1. Study flow diagram. The primary outcome was mortality, and the secondary outcome was treatment with maintenance dialysis.
doi:10.1371/journal.pmed.1001601.g001
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score (ranging from 0 to 4 for each of six organ systems with higher
scores indicating more severe organ dysfunction) [20].
Statistical Analysis
The analysis followed a statistical analysis plan developed prior
to any analysis of the study data (see Text S1). The dialysis-free
days outcome from this plan is presented in Table S1. The data
were analysed using SAS version 9.2. Where data were missing, we
report the number of available observations and make no
assumptions about missing values. Analyses were unadjusted,
except where indicated. All tests were two-sided with a nominal
value of a=0.05. Discrete variables were summarised by
frequencies and percentages; continuous variables by mean and
standard deviation (SD) or median and interquartile range (IQR)
where appropriate. Univariate analysis was performed using chi-
square tests for binary outcomes and Student t-tests for normally
distributed outcomes.
The long-term survival was analysed according to two
approaches: (1) from the time of patient randomization into the
RENAL study, (2) from 90 days following randomization into the
RENAL study (the final follow-up point for the RENAL Study).
Data were censored at the time when the patient was last known
to be alive. Survival curves and estimated median survival time (if
available) and 95% confidence interval were generated according
to the Kaplan-Meier method. The log-rank test was used to
assess the difference between the two survival curves. Mortality
beyond 90 days following randomization underwent multivariate
analysis using Cox modelling using backward stepwise regression
for variable selection (eliminating variables with p-values
.0.05) and forced inclusion of the RENAL study treatment
variable.
As death and chronic dialysis treatment are competing risks, a
competing risk sensitivity analysis was performed between the two
events. This analysis was based on the cumulative incidence
Table 1. Baseline characteristics by study treatment allocation of participants alive at day 90 and those consenting to clinical
follow-up in the POST-RENAL study.
Characteristic Alive at Day 90 (n=810) Consented to Clinical Follow-up (n=350)
Lower Intensity Higher Intensity Lower Intensity Higher Intensity
Number of participants 411 399 188 162
Age in years 62.5 (16) 62.9 (15) 61.3 (16) 62.2 (14)
Male sex n (%) 260 (63.3) 257 (64.4) 133 (70.7) 112 (69.1)
Mean preadmission eGFRa 58.7 (28) 52.7 (32) 59.9 (27) 56.1 (30)
Time in ICU before randomization (h, median 6 IQR) 4 (18–45) 5 (18–48) 7 (24–57 6 (17–45)
Mechanical ventilation – n (%) 281 (68.4) 266 (66.7) 135 (71.8) 113 (69.8)
Severe sepsis – n (%) 177 (43.1) 191 (47.9) 81 (43.1) 84 (51.9)
APACHE III score (mean 6 SD) 97.9 (24) 97 (23) 97.8 (23) 95.4 (23)
Weight – kg (mean 6 SD) 81.3 (13) 81.9 (13) 81.7 (13) 83 (13)
Non-operative primary diagnosis – n (% of total) 279 (67.8) 294 (73.6) 123 (65.4) 115 (70.9)
Cardiovascular (n, % of non-op) 138 (49.4) 142 (48.3) 65 (52.8) 62 (53.9)
Genitourinary (n, % of non-op) 75 (26.8) 82 (27.8) 26 (21.1) 29 (25.2)
Respiratory (n, % of non-op) 29 (10.4) 39 (13.3) 15 (12.2) 16 (13.9)
Gastrointestinal (n, % of non-op) 20 (7.2) 17 (5.8) 9 (7.3) 5 (4.3)
Other (n, % of non-op) 17 (6) 14 (4.8) 8 (6.5) 3 (2.7)
Operative primary admission diagnoses – n (% of total) 132 (32.1) 105 (26.3) 65 (34.6) 47 (29)
Cardiovascular (n, % of operative) 87 (65.9) 70 (66.7) 43 (66.1) 30 (63.8)
Gastrointestinal (n, % of operative) 25 (18.9) 23 (21.9) 13 (20) 11 (23.4)
Trauma (n, % of operative) 9 (6.8) 5 (4.8) 4 (6.2) 3 (6.4)
Other (n, % of operative) 11 (8.3) 7 (6.7) 5 (7.7) 3 (6.4)
Criteria for use of RRTb
Oliguria (n, %) 256 (62.2) 229 (57.4) 112 (59.6) 96 (59.3)
Hyperkalaemia (n, %) 31 (7.5) 40 (10) 11 (5.9) 15 (9.3)
Severe acidosis (n, %) 141 (34.3) 123 (30.8) 60 (31.9) 44 (27.2)
BUN . 25 mmol/l (n, %) 145 (35.3) 180 (45.1) 65 (34.3) 65 (40.1)
Creatinine . 300 mmol/l (n, %) 222 (54) 227 (56.9) 99 (52.7) 89 (54.9)
Severe organ oedema associated with AKI (n, %) 174 (42.3) 174 (43.6) 75 (39.9) 67 (41.4)
BUN (mmol/l, mean 6 SD) 22.2 (12) 24.4 (13) 21.5 (11) 22.6 (13)
Creatinine before randomization (mmol/l, mean 6 SD) 136 (115) 156 (117) 133 (123) 143 (88)
Bicarbonate (mmol/l, mean 6 SD) 18.3 (5.9) 18.0 (5.4) 18.7 (6.3) 18.5 (5.7)
aPre-admission renal function was only available on 433/810 (53%) of day 90 survivors of the RENAL Study.
bPercentage adds up to .100 owing to the presence of more than 1 criteria in some patients
doi:10.1371/journal.pmed.1001601.t001
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Figure 2. Kaplan-Meier survival curve for all study participants from randomization to end of extended follow-up, shown by
treatment group.
doi:10.1371/journal.pmed.1001601.g002
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Figure 3. Kaplan-Meier survival curve censoring deaths before day 90 of follow-up (end point of the RENAL Study follow-up),
shown by treatment group.
doi:10.1371/journal.pmed.1001601.g003
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Of the 1,508 patients randomized, 810 patients survived to day
90 after randomization (Figure 1), with 552 of these survivors
(68%) alive at the time of the POST-RENAL study. Tertiary
outcomes were available on 350 (63%) of these survivors who
consented to follow-up between August 2010 and January 2012.
The baseline characteristics of all RENAL Study participants
have been previously reported, and those of the 810 survivors at
day 90 and of the 350 consenting to clinical follow-up are
presented in Table 1.
Outcomes
Primary and secondary outcomes were derived at a median of
42.4 months (IQR 30.0–48.6 months) post randomization. There
were a further 258 deaths during the POST-RENAL study (122 in
the lower intensity group, 136 in the higher intensity group), giving
an overall mortality rate of 62% in the study cohort (Figure 2).
Median survival from randomization was 8.9 months in the
lower intensity group and 8.1 months in the higher intensity group
(RR 1.04, 95% CI 1.12, p=0.49) (Figure 2). Excluding deaths
before day 90, mortality in the lower intensity group was 122 of
411 (29.7%) and in the higher intensity group was 136 of 399
(34.1%) (RR 1.15, 95% CI 0.94–1.40, p=0.26) (Figure 3). Causes
of death beyond day 90 were similar in the two groups (Table 2),
with more deaths in the higher intensity group ascribed to
infectious causes (22 versus 35 deaths, p=0.05).
Forty-four patients (5.4% of those alive at day 90) were treated
with maintenance dialysis (Figure 4), 21 of 411 (5.1%) in the lower
intensity group and 23 of 399 (5.8%) in the higher intensity group
(RR 1.12, 95% CI 0.63–2.00, p=0.69). Thirty-four of these
patients (77.2%) entered the maintenance dialysis program before
day 90 following randomization, and ten (22.8%) entered after day
90. The cumulative incidence of the competing outcomes of death
or treatment with chronic dialysis is illustrated in Figure 4. Of the
12 patients whose death was ascribed to renal failure, two had
entered a dialysis program before death.
The tertiary outcomes are presented in Table 3. The mean
eGFR in participating survivors was 58 ml/min/1.73 m2 and the
prevalence of micro- or macro-albuminuria was 123/292 (42.1%),
the values were similar in the two study groups (p=0.72, and
p=0.48, respectively) (Table 3). Table 4 illustrates the cross
tabulation of eGFR and albuminuria based upon recent guideline
recommendations [22]. The only statistically significant difference
between the two study groups in any of the tertiary outcomes was a
higher diastolic blood pressure in the higher intensity group. In
view of the number of outcomes analysed, this finding may be due
to chance alone.
Quality of life in participating survivors, as measured using the
EQ-5D composite index, was not different between the two study
groups, with mean scores of 0.8 in the lower intensity group and
0.7 in the higher intensity group (SD=0.3, p=0.70) (Table S2).
The SF-12 physical composite scores (mean 6 SD, lower intensity
41.1612 versus higher intensity 49.8611, p=0.34) and the SF-12
mental composite scores (49.6612 versus 49.4611, p=0.89)
among survivors were not different between the two study
treatments.
Multivariate Predictors of Long-Term Mortality
Results of the univariate Cox modelling of the long-term
mortality from randomization are presented in Table S3. The
results of the multivariate Cox models are summarized in Figure 5
and Table 5. Increasing age of participants, divided using quartiles
with the lowest age group (,56 years at randomization) as the
reference, revealed incremental increases in mortality with age.
After adjustment for other variables in the multivariate model,
patients ,56 years of age at randomization had a mortality of
48% at 3.5 years, compared to 71% in those aged .76 years
(Figure 5). Other baseline variables that were statistically
significant predictors of mortality on multivariate modelling were
Table 2. Causes of death during the POST-RENAL study (beyond day 90 of RENAL Study).
Cause of Death Lower Intensity N (% of total) Higher Intensity N (% of total) p-Value
Infectious causes 0.05
Pneumonia 6 (4.9%) 19 (14%)
Other infection/septicaemia 16 (13.1%) 16 (11.7%)
Cardiovascular causes 0.47
Ischaemic heart disease 16 (13.1%) 17 (12.5%)
Cardiac failure 12 (9.8%) 8 (5.9%)
Other vascular disease 5 (4.1%) 10 (7.4%)
Malignancy 0.12
Cancer 17 (13.9%) 29 (21.3%)
Haematological malignancy 7 (5.7%) 3 (2.2%)
Metabolic 0.24
Respiratory failure 9 (7.4%) 5 (3.7%)
Renal failure 6 (4.9%) 6 (4.4%)
Liver failure 7 (5.7%) 3 (2.2%)
Other or unknown 21 (17.2%) 20 (14.7%) 0.58
Total 122 136
p-Values refer to differences across the category of death by treatment allocation.
doi:10.1371/journal.pmed.1001601.t002
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APACHE III score and serum creatinine at randomization. Study
treatment intensity did not influence mortality.
Discussion
Statement of Key Findings
We conducted an extended follow-up of patients randomized to
a large study of ICU patients requiring RRT for AKI to establish
the long-term mortality rate, the need for maintenance dialysis,
prevalence of renal dysfunction, and the quality of life among
survivors. We found that patients with AKI treated with RRT in
the ICU were at high risk of dying during the 3.5-year follow-up
period; overall 31.9% of those surviving to 90 days died during the
extended follow-up period. The risk of dying was much greater
than the risk of entering a maintenance dialysis program, with
neither outcome being influenced by the use of a higher intensity
of RRT. The rate of albuminuria in survivors was substantial,
despite relative preservation of renal function.
Relationship to Existing Literature
Existing data on the long-term consequences of an episode of
AKI are largely derived from administrative or disease specific
cohorts [10,23]. The absolute rates of CKD development and
mortality reported from these studies have been highly variable
[11], likely reflecting the different study designs and selection
criteria, with pooled rates of 25.8 per 100 person years and 16.8
per 100 person years, respectively. The pooled relative risks from
these studies, compared to non-AKI patients, of any CKD
development following an episode of AKI was 8.8, for the
development of end-stage kidney disease was 3.1, and for mortality
was 2.0 [11]. The nature of these studies and their reporting has
contributed to a perception that the risk of renal disease
Figure 4. Cumulative incidence functions, comparing time to the first event of either the requirement for chronic dialysis or death
beyond day 90 following randomization (each curve shown by treatment group).
doi:10.1371/journal.pmed.1001601.g004
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progression should be of primary concern in such patients. Our
findings differ from many of these reports and these discrepancies
are likely to be due to differences in the populations studied and
the methodologies used. In particular, previous reports have not
specifically targeted patients with AKI requiring RRT in the ICU,
and such patients are at greater risk of dying compared with
general hospital patients with AKI, as shown in a Swedish study of
similar patients [23].
The paucity of prospective data has also limited our
understanding of the natural history of AKI. Independent of
eGFR, chronic proteinuria is a risk factor for death, cardiovas-
cular disease, and the later requirement for dialysis [24,25].
However, the prevalence of this risk factor following an episode of
AKI has remained uncertain. Data from a broader population in
Australia report a prevalence of proteinuria of 2.4% in the entire
population that increases to 6.6% in those over 65 years of age
[26]. Data from the National Health and Nutrition Examination
Surveys cite a prevalence of 9.5% for albuminuria [27], and
further data from a provincial laboratory registry in Canada
report a prevalence of 25% using the ACR [28]. The degree of
proteinuria in our study population prior to their renal injury is
not known, but these other reports would suggest it is likely to be
substantially less than the rate seen after the AKI in our study.
Using recent classifications of CKD that include both eGFR and
proteinuria to predict future risk of events [28], 13% of the
survivors in our study population are in the highest risk group for
death or renal functional decline.
The quality of life of survivors following treatment with RRT
for AKI in the ICU has been described in a limited number of
centres or shortly following the index hospitalization. Delannoy
and colleagues [29] reported quality of life at six months following
hospitalisation in seven centres; their results are consistent with
ours, with very similar SF-12 physical and mental composite
scores. When compared to a general population cohort with an
eGFR , 60 ml/min/1.73 m2 in the Australian Diabetes, Obesity
and Lifestyle Study [30], the SF-12 physical and mental
component scores in our patients were similar. The EQ-5D
composite scores in our severe AKI survivors most closely
approximate those seen in renal transplant recipients [31].
Implications of Study Findings
Our study highlights the increased long-term risk of death
associated with AKI treated with RRT in an ICU. Only one-third
of randomized patients were alive 3.5 years later, a lower survival
than that seen in recognised high mortality conditions such as the
acute respiratory distress syndrome [32]. Although, in our patients
the risk of subsequent maintenance dialysis dependence is low,
almost half have evidence of significant proteinuria, portending
further risk in the years to come. These findings support the view
that survivors of AKI are at increased risk and that closer
surveillance may be justified. In addition, our findings suggest that
chronic proteinuria reduction strategies, which have shown benefit
in some patient groups with proteinuria, may warrant investiga-
tion as a therapeutic intervention.
Study Strengths and Limitations
The strength of these findings lies in the prospective nature of
the study along with the scale and completeness of long-term
follow-up. The design allows for greater precision in estimates of
absolute risk and enhances the clinical applicability of the findings
Table 3. Clinical and biochemical outcomes in extended follow-up participants.
Outcomes n Analysed All Participants Lower Intensity Higher Intensity p-Values
n blood pressure lowering medications (mean 6 SD) 350 1.7 (0.9) 1.9 (1.0) 1.6 (0.8) 0.45
Systolic blood pressure (mm Hg, mean 6 SD) 340 132 (18) 131 (16) 133 (20) 0.17
Diastolic blood pressure (mm Hg, mean 6 SD) 339 74.8 (12) 73.4 (11) 76.3 (12) 0.02
Serum creatinine at follow-up (mmol/l, mean 6 SD) 343 150 (136) 146 (120) 154 (153) 0.59
eGFR at follow-up (ml/min/1.73 m2, mean 6 SD) 343 58 (30) 58 (29) 59 (30) 0.72
Change in creatinine from baseline to follow-up
(mmol/l, mean 6 SD)a
343 2202 (196) 2204 (207) 2200 (183) 0.87
Change in eGFR from baseline to follow-up (ml/min/
1.73 m2, mean 6 SD)a
343 38 (29) 38 (29) 39 (30) 0.69
Urinary ACR (mg/mmol, mean 6 SD) 292 0.7 (2–7.5) 0.7 (2.4–8.7) 0.7 (1.9–6.3) 0.55
Urinary ACR # 3.5 mg/mmol (n, %) 292 172 (58.9) 86 (56.6) 86 (61.4) 0.45
Urinary ACR . 3.5 and # 35 mg/mmol (n, %) 292 94 (32.1) 53 (34.9) 41 (29.3) 0.28
Urinary ACR .35 (n, %) 292 29 (9.9) 14 (9.2) 15 (10.7) 0.68
Micro or macro-albuminuria (n,%) 292 123 (42.1) 67 (44.1) 56 (40) 0.48
aDifference between baseline serum creatinine and eGFR from the RENAL study (just prior to acute RRT initiation) and POST-RENAL study clinical follow-up.
doi:10.1371/journal.pmed.1001601.t003
Table 4. Prevalence of CKD by eGFR and albumin to
creatinine ratio in follow-up participants.
eGFR Categories
ml/min/1.73 m2 Urine ACR Categories (mg/mmol)
,3 $3 and #30 .30
$90 30 11 1
60–89 74 25 1
45–59 33 20 3
30–44 18 24 3
15–29 5 19 11
,15 2 1 12
Total 162 100 31
Two patients with an ACR performed have missing eGFR measurement.
doi:10.1371/journal.pmed.1001601.t004
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whilst avoiding potential bias from retrospective selection of the
study cohort. However, a further consequence of such a study
design is that the findings from a randomized trial are not always
generalizable to other patient populations, so caution should be
applied in extrapolating these findings from an ICU cohort to
other patients with AKI. In addition, while data linkage has
allowed near complete follow-up of mortality and maintenance
dialysis outcomes, the clinical and biochemical outcomes were
only available for a consenting sub-group that might not be
representative of the broader cohort.
Summary
In a large cohort of patients with AKI randomized to differing
doses of continuous RRT in the ICU, the increased risk of
death continues well beyond hospital discharge and is not
altered by increased intensity of dialysis. The proportion of
patients entering a maintenance dialysis program is small but
there is a high prevalence of proteinuria amongst survivors
suggesting significant ongoing risk of chronic kidney disease and
mortality.
Supporting Information
Table S1 Dialysis-free days outcome.
(DOCX)
Table S2 Other quality of life outcomes.
(DOCX)
Table S3 Univariate Cox model for mortality.
(DOCX)
Text S1 Statistical analysis plan.
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Figure 5. Adjusted Cox model survival curves from randomization, stratified by quartiles of age.
doi:10.1371/journal.pmed.1001601.g005
Table 5. Cox multivariate model for long-term mortality from randomization.
Variable Comparator Hazard Ratio (95% CI) p-Value
Age (by quartiles) ,56 years (index)
56–67 years 1.39 (1.14–1.70) 0.001
67–76 years 1.52 (1.24–1.85) ,0.001
.76 years 1.85 (1.53–2.25) ,0.001
Study treatment Higher vs lower dose 1.07 (0.94–1.22) 0.32
APACHE III score 10 unit increase 1.12 (1.09–1.15) ,0.001
Randomization serum creatinine 44 mmol/l increase 0.96 (0.94–0.97) ,0.001
doi:10.1371/journal.pmed.1001601.t005
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Editors’ Summary
Background. Throughout life, the kidneys perform the
essential task of filtering waste products (from the normal
breakdown of tissues and from food) and excess water from
the blood to make urine. Chronic kidney disease (caused, for
example, by diabetes) gradually destroys the kidneys’
filtration units (the nephrons), eventually leading to life-
threatening end-stage kidney disease. However, the kidneys
can also stop working suddenly because of injury, infection,
or poisoning. Acute kidney injury (AKI) is much more
common than end-stage kidney disease and its incidence
is increasing worldwide. In the US, for example, the number
of hospitalizations that included an AKI diagnosis rose from
4,000 in 1996 to 23,000 in 2008. Moreover, nearly half of
patients with AKI will die shortly after the condition
develops. Symptoms of AKI include changes in urination,
swollen feet and ankles, and tiredness. Treatments for AKI
aim to prevent fluid and waste build up in the body and treat
the underlying cause (e.g., severe infection or dehydration)
while allowing the kidneys time to recover. In some patients,
it is sufficient to limit the fluid intake and to reduce waste
build-up by eating a diet that is low in protein, salt, and
potassium. Other patients need renal replacement therapy
(RRT), life-supporting treatments such as hemodialysis and
hemofiltration, two processes that clean the blood by
filtering it outside the body.
Why Was This Study Done? The long-term outcomes of
AKI (specifically, death and chronic kidney disease) and the
effects of different RRT modalities on these outcomes are
unclear. A recent controlled trial that randomly assigned
patients with AKI who were managed in intensive care units
(ICUs) to receive two different intensities of continuous
hemodiafiltration (a combination of hemodialysis and hemo-
filtration) found no difference in all-cause mortality (death) at
90 days. Here, the researchers extend the follow-up of this trial
(the Randomized Evaluation of Normal vs. Augmented Levels
of renal replacement therapy [RENAL] study) to investigate
longer-term mortality, the variables that predict mortality,
treatment with long-term dialysis (an indicator of chronic
kidney disease), and functional outcomes in patients with AKI
treated with different intensities of continuous RRT.
What Did the Researchers Do and Find? For the
Prolonged Outcomes Study of RENAL (POST-RENAL), the
researchers extended the follow-up of the RENAL partici-
pants up to 4 years. Over an average follow-up of 43.9
months, 63% of patients in the lower intensity treatment
group died compared to 62% of patients in the higher
intensity group. Overall, a third of patients who survived to
90 days died during the extended follow-up. Among the
survivors to day 90, 5.1% and 5.8% of patients in the lower
and higher intensity groups, respectively, were treated with
maintenance dialysis during the extended follow-up. Among
survivors who consented to analysis, 40% and 44% of
patients in the lower and higher intensity groups, respec-
tively, had albuminuria (protein in the urine, an indicator of
kidney damage). Patients in both groups had a similar quality
life (determined through telephone interviews). Finally,
increasing age, APACHE III score (a scoring system that
predicts the survival of patients in ICU), and serum creatinine
level (an indicator of kidney function) at randomization were
all predictors of long-term mortality.
What Do These Findings Mean? These findings indicate
that patients with AKI in ICUs who require RRT have a high
long-term mortality. They show that few survivors require
maintenance dialysis for chronic kidney disease but that
there is a substantial rate of albuminuria among survivors
despite relative preservation of kidney function. The findings
also suggest that the intensity of RRT has no significant
effect on mortality or the need for dialysis. Because these
findings were obtained in a randomized controlled trial, they
may not be generalizable to other patient populations.
Moreover, although data on mortality and maintenance
dialysis were available for all the trial participants, clinical and
biochemical outcomes were only available for some partic-
ipants and may not be representative of all the participants.
Despite these study limitations, these findings suggest that
survivors of AKI may be at a high risk of death or of
developing chronic kidney disease. Survivors of AKI are,
therefore, at high risk of further illness and long-term
albuminuria reduction strategies may offer a therapeutic
intervention for this group of patients.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001601.
N The US National Kidney and Urologic Diseases Information
Clearinghouse provides information about the kidneys and
about all aspects of kidney disease and its treatment; the
US National Kidney Disease Education Program provides
resources to help improve the understanding, detection,
and management of kidney disease (in English and
Spanish)
N The Mayo Clinic provides information for patients about
acute kidney injury
N Wikipedia has a page on acute kidney injury (note that
Wikipedia is a free online encyclopedia that anyone can
edit; available in several languages)
N The not-for-profit UK National Kidney Federation provides
support and information for patients with kidney disease
and for their carers, including a link to a video about acute
kidney injury
N World Kidney Day, a joint initiative between the Interna-
tional Society of Nephrology and the International
Federation of Kidney Foundations (IFKF), aims to raise
awareness about kidneys and kidney disease; its website
provides information about acute kidney injury
N The MedlinePlus Encyclopedia has a pages about acute
kidney failure and about renal dialysis
N The UK National Institute for Health and Care Excellence
(NICE) recently published new guidelines on the treatment
of acute kidney injury; a clinical practice guideline for acute
kidney injury produced by KDIGO (a not-for-profit organi-
zation that aims to improve the care and outcomes of
kidney disease patients worldwide through the develop-
ment and implementation of global clinical practice
guidelines) is available; the Acute Kidney Injury app
provides a fast and simple way to explore guidelines on
the diagnosis, prevention, and management of AKI
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